Full Text Journal Articles by
Author Bas W van Rhijn

Advertisement

Find full text journal articles






Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.

Francesco Claps, Maaike W van de Kamp, Roman Mayr, Peter J Bostrom, Joost L Boormans, Markus Eckstein, Laura S Mertens, Egbert R Boevé, Yann Neuzillet, Maximilian Burger, Damien Pouessel, Carlo Trombetta, Bernd Wullich, Theo H van der Kwast, Arndt Hartmann, Yves Allory, Yair Lotan, Shahrokh F Shariat, Tahlita C M Zuiverloon, M Carmen Mir, Bas W G van Rhijn,

<h4>Purpose</h4>To evaluate the risk factors associated with positive surgical margins' (PSMs) location and their impact on disease-specific survival (DSS) in patients with bladder cancer (BCa) undergoing radical cystectomy (RC).<h4>Methods</h4>We analyzed a large multi-institutional cohort of patients treated with upfront RC for non-metastatic (cT1-4aN0M0) BCa. Multivariable binomial logistic regression analyses were ... Read more >>

World J Urol (World journal of urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy.

Francesco Claps, Samarpit Rai, Maria Carmen Mir, Bas W G van Rhijn, Giorgio Mazzon, Laura Elizabeth Davis, Crystal Lynn Valadon, Tommaso Silvestri, Michele Rizzo, Murali Ankem, Giovanni Liguori, Antonio Celia, Carlo Trombetta, Nicola Pavan,

<h4>Introduction and objectives</h4>To evaluate the prognostic role of albumin-to-fibrinogen ratio (AFR) for the prediction of oncological outcomes in a multi-institutional cohort of bladder cancer (BC) patients treated with radical cystectomy (RC).<h4>Materials and methods</h4>We retrospectively analyzed a multicenter cohort of patients treated with upfront RC for localized (cT1-4aN0M0) BC. Multivariable logistic ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer.

David D'Andrea, Francesco Soria, Anne J Grotenhuis, Eugene K Cha, Nuria Malats, Savino Di Stasi, Steven Joniau, Tommaso Cai, Bas W G van Rhijn, Jaques Irani, Jeffrey Karnes, John Varkarakis, Jack Baniel, Joan Palou, Marek Babjuk, Martin Spahn, Peter Ardelt, Renzo Colombo, Vincenzo Serretta, Guido Dalbagni, Paolo Gontero, Riccardo Bartoletti, Stephane Larré, Per-Uno Malmstrom, Richard Sylvester, Shahrokh F Shariat,

<h4>Purpose</h4>To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guérin (BCG) for T1G3/HG urinary bladder cancer (UBC).<h4>Materials and methods</h4>We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing ... Read more >>

World J Urol (World journal of urology)
[2021, :]

Cited: 1 time

View full text PDF listing >>



International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma.

Theo van der Kwast, Fredrik Liedberg, Peter C Black, Ashish Kamat, Bas W G van Rhijn, Ferran Algaba, David M Berman, Arndt Hartmann, Antonio Lopez-Beltran, Hemamali Samaratunga, Murali Varma, Liang Cheng,

<h4>Context</h4>Grading is the mainstay for treatment decisions for patients with non-muscle-invasive bladder cancer (NMIBC).<h4>Objective</h4>To determine the requirements for an optimal grading system for NMIBC via expert opinion.<h4>Evidence acquisition</h4>A multidisciplinary working group established by the International Society of Urological Pathology reviewed available clinical, histopathological, and molecular evidence for an optimal grading ... Read more >>

Eur Urol Focus (European urology focus)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The Diagnostic Value of FDG-PET/CT for Urachal Cancer.

Laura E Stokkel, Marcel P M Stokkel, Maarten L Donswijk, Max J Lahaye, Elise M Bekers, Bas W G van Rhijn, Laura S Mertens,

<h4>Background</h4>Urachal carcinoma (UrC) is a rare malignancy that often presents at an advanced stage with metastases in up to a quarter of patients. There is no consensus on the optimal form of staging for patients with UrC. In the present study, we evaluated the diagnostic value of <sup>18</sup>F-fluorodeoxyglucose-positron emitted tomography/computed ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.

Richard J Sylvester, Oscar Rodríguez, Virginia Hernández, Diana Turturica, Lenka Bauerová, Harman Max Bruins, Johannes Bründl, Theo H van der Kwast, Antonin Brisuda, José Rubio-Briones, Maximilian Seles, Anouk E Hentschel, Venkata R M Kusuma, Nicolai Huebner, Juliette Cotte, Laura S Mertens, Dimitrios Volanis, Olivier Cussenot, Jose D Subiela Henríquez, Enrique de la Peña, Francesca Pisano, Michael Pešl, Antoine G van der Heijden, Sonja Herdegen, Alexandre R Zlotta, Jaromir Hacek, Ana Calatrava, Sebastian Mannweiler, Judith Bosschieter, David Ashabere, Andrea Haitel, Jean-François Côté, Soha El Sheikh, Luca Lunelli, Ferran Algaba, Isabel Alemany, Francesco Soria, Willemien Runneboom, Johannes Breyer, Jakko A Nieuwenhuijzen, Carlos Llorente, Luca Molinaro, Christina A Hulsbergen-van de Kaa, Matthias Evert, Lambertus A L M Kiemeney, James N'Dow, Karin Plass, Otakar Čapoun, Viktor Soukup, Jose L Dominguez-Escrig, Daniel Cohen, Joan Palou, Paolo Gontero, Maximilian Burger, Richard Zigeuner, Amir Hugh Mostafid, Shahrokh F Shariat, Morgan Rouprêt, Eva M Compérat, Marko Babjuk, Bas W G van Rhijn,

<h4>Background</h4>The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based ... Read more >>

Eur Urol (European urology)
[2021, 79(4):480-488]

Cited: 2 times

View full text PDF listing >>



Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer.

Anke Richters, Theodora M Ripping, Lambertus A Kiemeney, Anna M Leliveld, Bas W G van Rhijn, Jorg R Oddens, R Jeroen A van Moorselaar, Catharina A Goossens-Laan, Richard P Meijer, Joost L Boormans, , J Alfred Witjes, Katja K H Aben,

<h4>Objective</h4>To contribute to the debate regarding the minimum volume of radical cystectomies (RCs) that a hospital should perform by evaluating the association between hospital volume (HV) and postoperative mortality.<h4>Patients and methods</h4>Patients who underwent RC for bladder cancer between 1 January 2008 and 31 December 2018 were retrospectively identified from the ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer.

Charlotte S Voskuilen, Erik J van Gennep, Sarah M H Einerhand, Erik Vegt, Maarten L Donswijk, Annemarie Bruining, Henk G van der Poel, Simon Horenblas, Kees Hendricksen, Bas W G van Rhijn, Laura S Mertens,

Given the high risk of systemic relapse following initial therapy for muscle-invasive bladder cancer (MIBC), improved pretreatment staging is needed. We evaluated the incremental value of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) after standard conventional staging, in the largest cohort of MIBC patients to date. This is a retrospective analysis ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.

Bas W G van Rhijn, Anouk E Hentschel, Johannes Bründl, Eva M Compérat, Virginia Hernández, Otakar Čapoun, H Maxim Bruins, Daniel Cohen, Morgan Rouprêt, Shahrokh F Shariat, A Hugh Mostafid, Richard Zigeuner, Jose L Dominguez-Escrig, Maximilian Burger, Viktor Soukup, Paolo Gontero, Joan Palou, Theo H van der Kwast, Marko Babjuk, Richard J Sylvester, ,

<h4>Background</h4>In the current European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guideline, two classification systems for grade are advocated: WHO1973 and WHO2004/2016.<h4>Objective</h4>To compare the prognostic value of these WHO systems.<h4>Design, setting, and participants</h4>Individual patient data for 5145 primary Ta/T1 NMIBC patients from 17 centers were collected between 1990 and ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, 4(2):182-191]

Cited: 0 times

View full text PDF listing >>



Sexual Satisfaction in Men Suffering From Erectile Dysfunction After Robot-Assisted Radical Prostatectomy for Prostate Cancer: An Observational Study.

Leonore F Albers, Corinne N Tillier, Erik van Muilekom, Erik van Werkhoven, Henk W Elzevier, Bas W G van Rhijn, Henk G van der Poel, Kees Hendricksen,

<h4>Background</h4>Preservation of erectile function is an important postoperative quality of life concern for patients after robot-assisted radical prostatectomy (RARP) for prostate cancer. Although erectile function may recover, many men continue to suffer from erectile dysfunction (ED).<h4>Aim</h4>This study aims to determine whether satisfaction with sexual life improves in patients with ED ... Read more >>

J Sex Med (The journal of sexual medicine)
[2021, 18(2):339-346]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.

Francesco Soria, Peter C Black, Adrian S Fairey, Michael S Cookson, Evan Y Yu, Wassim Kassouf, Marc A Dall'Era, Srikala S Sridhar, John S McGrath, Jonathan L Wright, Andrew C Thorpe, Todd M Morgan, Siamak Daneshmand, Jeff M Holzbeierlein, Trinity J Bivalacqua, Scott North, Daniel A Barocas, Yair Lotan, Petros Grivas, Andrew J Stephenson, Jay B Shah, Bas W van Rhijn, Philippe E Spiess, Shahrokh F Shariat, Paolo Gontero,

<h4>Objectives</h4>To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicentre cohort of patients with cT2N0M0 bladder cancer (BCa) without preoperative hydronephrosis.<h4>Patients and methods</h4>This was a propensity-based analysis of 619 patients. Of these, 316 were treated with NAC followed by RC and 303 with upfront ... Read more >>

BJU Int (BJU international)
[2021, 128(1):79-87]

Cited: 2 times

View full text PDF listing >>



Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer.

Theodora M Ripping, J Alfred Witjes, Richard P Meijer, Bas W G van Rhijn, Jorg R Oddens, Catharina A Goossens-Laan, Sasja F Mulder, Reindert J A van Moorselaar, Lambertus A Kiemeney, Katja K H Aben,

<h4>Objectives</h4>Radical cystectomies (RCs) are increasingly centralized, but bladder cancer can be diagnosed in every hospital The aim of this study is to assess the variation between hospitals of diagnosis in a patient's chance to undergo a RC before and after the volume criteria for RCs, to identify factors associated with ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(12):935.e9-935.e16]

Cited: 0 times

View full text PDF listing >>



Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.

David D'Andrea, Surena Matin, Peter C Black, Firas G Petros, Homayoun Zargar, Colin P Dinney, Michael S Cookson, Wassim Kassouf, Marc A Dall'Era, John S McGrath, Jonathan L Wright, Andrew C Thorpe, Todd M Morgan, Jeffrey M Holzbeierlein, Trinity J Bivalacqua, Srikala S Sridhar, Scott North, Daniel A Barocas, Yair Lotan, Andrew J Stephenson, Bas W van Rhijn, Philippe E Spiess, Siamak Daneshmand, Shahrokh F Shariat,

<h4>Objective</h4>To assess the differential response to neoadjuvant chemotherapy (NAC) in patients with urothelial carcinoma of the bladder (UCB) compared to upper tract urothelial carcioma (UTUC) treated with radical surgery.<h4>Patients and methods</h4>Data from 1299 patients with UCB and 276 with UTUC were obtained from multicentric collaborations. The association of disease location ... Read more >>

BJU Int (BJU international)
[2021, 127(5):528-537]

Cited: 0 times

View full text PDF listing >>



The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.

Thomas van Doeveren, Jose A Nakauma-Gonzalez, Jose A Nakauma-Gonzalez, Andrew S Mason, Geert J L H van Leenders, Tahlita C M Zuiverloon, Ellen C Zwarthoff, Isabelle C Meijssen, Angelique C van der Made, Antoine G van der Heijden, Kees Hendricksen, Bas W G van Rhijn, Charlotte S Voskuilen, Job van Riet, Winand N M Dinjens, Hendrikus J Dubbink, Harmen J G van de Werken, Joost L Boormans,

The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma (UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains whether UTUC and the subsequent UCB are clonally related or represent separate ... Read more >>

Int J Cancer (International journal of cancer)
[2021, 148(4):981-987]

Cited: 2 times

View full text PDF listing >>



The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancer.

Maximilian Haas, Toni Huber, Christoph Pickl, Bas W G van Rhijn, Miodrag Gužvić, Michael Gierth, Johannes Breyer, Maximilian Burger, Roman Mayr,

<h4>Objective</h4>To assess the true cumulative morbidity after RC by implementing the Comprehensive Complication Index (CCI) over a 90-day period, since recent evidence suggests underreporting of the cumulative morbidity after radical cystectomy (RC) with inconsistent complication rates when reported with conventional reporting systems.<h4>Patients and methods</h4>Medical records of 433 patients with bladder ... Read more >>

Eur J Surg Oncol (European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology)
[2021, 47(5):1163-1171]

Cited: 0 times

View full text PDF listing >>



Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

Nick van Dijk, Alberto Gil-Jimenez, Karina Silina, Kees Hendricksen, Laura A Smit, Jeantine M de Feijter, Maurits L van Montfoort, Charlotte van Rooijen, Dennis Peters, Annegien Broeks, Henk G van der Poel, Annemarie Bruining, Yoni Lubeck, Karolina Sikorska, Thierry N Boellaard, Pia Kvistborg, Daniel J Vis, Erik Hooijberg, Ton N Schumacher, Maries van den Broek, Lodewyk F A Wessels, Christian U Blank, Bas W van Rhijn, Michiel S van der Heijden,

Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown remarkable pathological responses in melanoma<sup>1</sup> and colorectal cancer<sup>2</sup>. In NABUCCO (ClinicalTrials.gov: NCT03387761 ), a single-arm feasibility trial, 24 patients with stage III urothelial cancer (UC) received two doses of ipilimumab and two doses of nivolumab, followed by resection. The primary endpoint ... Read more >>

Nat Med (Nature medicine)
[2020, 26(12):1839-1844]

Cited: 12 times

View full text PDF listing >>



The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC).

Beat Foerster, Mohammad Abufaraj, Andrea Mari, Thomas Seisen, Marco Bandini, Donald Schweitzer, Anna K Czech, Marco Moschini, David D'Andrea, Marco Bianchi, Kees Hendricksen, Morgan Rouprêt, Alberto Briganti, Bas W G van Rhijn, Piotr Chłosta, Pierre Colin, Hubert John, Shahrokh F Shariat,

<h4>Introduction</h4>The objective of this study was to evaluate the performance of different tumor diameters for identifying ≥ pT2 upper tract urothelial carcinoma (UTUC) at radical nephroureterectomy.<h4>Patients and methods</h4>This was a multi-institutional retrospective study that included 932 patients who underwent radical nephroureterectomy for nonmetastatic UTUC between 2000 and 2016. Tumor sizes were ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, 19(3):272.e1-272.e7]

Cited: 0 times

View full text PDF listing >>



18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.

Sarah M H Einerhand, Erik J van Gennep, Laura S Mertens, Kees Hendricksen, Maarten L Donswijk, Henk G van der Poel, Bas W G van Rhijn,

<h4>Purpose of review</h4>In this narrative review, we assessed the role of F-fluoro-2-deoxy-D-glucose-positron emission tomography/CT (FDG-PET/CT) in preoperative staging and response evaluation of neoadjuvant chemotherapy in muscle-invasive bladder carcinoma (MIBC), and to assess its incremental value to contrast-enhanced (CE)CT and MRI in terms of patient management at initial diagnosis and detection ... Read more >>

Curr Opin Urol (Current opinion in urology)
[2020, 30(5):654-664]

Cited: 0 times

View full text PDF listing >>



Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.

Anjelica Hodgson, Bas W G van Rhijn, Sung Sun Kim, Colleen Ding, Rola Saleeb, Danny Vesprini, Stanley K Liu, George M Yousef, Theodorus H van der Kwast, Bin Xu, Michelle R Downes,

FGFR3 mutations are frequently mutually exclusive of TP53 mutations in invasive high grade urothelial carcinoma (HGUC) and p53 immunohistochemistry is often used as a surrogate for TP53 mutations. A 10 % staining cut off has been used in HGUC for designation as p53 positive or negative however, a novel contemporary ... Read more >>

Pathol Res Pract (Pathology, research and practice)
[2020, 216(11):153186]

Cited: 1 time

View full text PDF listing >>



Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB).

T M Ripping, L A Kiemeney, L M C van Hoogstraten, J A Witjes, K K H Aben, ,

<h4>Background</h4>Despite the embedding of bladder cancer management in European guidelines, large variation in clinical practice exists for applied diagnostics and treatments. This variation may affect patients' outcomes including complications, disease recurrence, progression, survival, and health-related quality of life (HRQL). Lack of detailed clinical data and HRQL data hampers a comprehensive ... Read more >>

BMC Cancer (BMC cancer)
[2020, 20(1):455]

Cited: 1 time

View full text PDF listing >>



Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.

Charlotte S Voskuilen, Maaike W van de Kamp, Nannet Schuring, Laura S Mertens, Arjen Noordzij, Floris Pos, Bas W G van Rhijn, Michiel S van der Heijden, Eva E Schaake,

<h4>Background and purpose</h4>Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC). MMC/capecitabine is an effective replacement for 5FU as a radiosensitizer in other malignancies but has not been studied in bladder cancer. We evaluated the ... Read more >>

Radiother Oncol (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology)
[2020, 150:275-280]

Cited: 1 time

View full text PDF listing >>



FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?.

Bas W G van Rhijn, Laura S Mertens, Roman Mayr, Peter J Bostrom, Francisco X Real, Ellen C Zwarthoff, Joost L Boormans, Cheno Abas, Geert J L H van Leenders, Stefanie Götz, Katrin Hippe, Simone Bertz, Yann Neuzillet, Joyce Sanders, Annegien Broeks, Michiel S van der Heijden, Michael A S Jewett, Mirari Marquez, Robert Stoehr, Alexandre R Zlotta, Markus Eckstein, Yanish Soorojebally, Hossain Roshani, Maximilian Burger, Wolfgang Otto, François Radvanyi, Nanor Sirab, Damien Pouessel, Bernd Wullich, Theo H van der Kwast, Núria Malats, Arndt Hartmann, Yves Allory, Tahlita C M Zuiverloon,

Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with favorable BC prognosis. Overexpression was reported in up to 40% of FGFR3 wild-type muscle-invasive BC. We analyzed FGFR3 mutations, FGFR3, and p53 protein expression and assessed ... Read more >>

Eur Urol (European urology)
[2020, 78(5):682-687]

Cited: 2 times

View full text PDF listing >>



A testosterone-producing Leydig cell tumor metastasis during hormonal treatment of prostate cancer.

Laura Stokkel, Henk G van der Poel, Sigrun I Langbein, J Martijn Kerst, Jeroen de Jong, Bas W G van Rhijn,

We describe a patient with a testosterone-producing metastasis discovered during the follow-up of prostate cancer. The patient had a history of a Leydig cell tumor (LCT) in the right testicle for which he underwent radical orchiectomy at the age of 60 years. Within a year after orchiectomy, he was diagnosed ... Read more >>

Urol Ann (Urology annals)
[2020, 12(2):180-183]

Cited: 0 times

View full text PDF listing >>



The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group.

Philipp Gild, Malte W Vetterlein, Roland Seiler, Andrea Necchi, Kees Hendricksen, Laura S Mertens, Florian Roghmann, Nicolas V Landenberg, Paolo Gontero, Marcus Cumberbatch, Jakub Dobruch, Thomas Seisen, Pietro Grande, David D'Andrea, Julien Anract, Evi Comploj, Armin Pycha, Karim Saba, Cedric Poyet, Bas W van Rhijn, Aidan P Noon, Morgan Roupret, Shahrokh F Shariat, Margit Fisch, Evanguelos Xylinas, Michael Rink,

<h4>Objective</h4>To prospectively study the impact of smoking on pathological response to neoadjuvant chemotherapy (NAC) in patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB).<h4>Materials & methods</h4>We collected standard clinicopathological variables, including smoking status (never, former, current) in patients undergoing NAC and RC for UCB at 12 European ... Read more >>

Surg Oncol (Surgical oncology)
[2020, 34:312-317]

Cited: 1 time

View full text PDF listing >>



Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.

David D'Andrea, Peter C Black, Homayoun Zargar, Kamran Zargar-Shoshtari, Sonja Zehetmayer, Adrian S Fairey, Laura S Mertens, Colin P Dinney, Maria C Mir, Laura-Maria Krabbe, Michael S Cookson, Niels-Erik Jacobsen, Jeffrey S Montgomery, Nikhil Vasdev, Evan Y Yu, Evanguelos Xylinas, Nicholas J Campain, Wassim Kassouf, Marc A Dall'Era, Jo-An Seah, Cesar E Ercole, Simon Horenblas, Srikala S Sridhar, John S McGrath, Jonathan Aning, Jonathan L Wright, Andrew C Thorpe, Todd M Morgan, Jeffrey M Holzbeierlein, Trinity J Bivalacqua, Scott North, Daniel A Barocas, Yair Lotan, Petros Grivas, Andrew J Stephenson, Jay B Shah, Bas W van Rhijn, Siamak Daneshmand, Philippe E Spiess, Shahrokh F Shariat,

<h4>Objective</h4>To assess the effect of patient's sex on response to neoadjuvant chemotherapy (NAC) in patients with clinically nonmetastatic muscle-invasive bladder cancer (MIBC).<h4>Methods</h4>Complete pathologic response, defined as ypT0N0 at radical cystectomy, and downstaging were evaluated using sex-adjusted univariable and multivariable logistic regression modeling. We used interaction terms to account for age ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(7):639.e1-639.e9]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.3509 s